CIRSE Launches Study of TACE With Terumo's LifePearl Microspheres to Treat Metastatic Liver Disease


May 5, 2017—The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) announced the launch of the CIRSE Registry for LifePearl Microspheres (CIREL) observational study. The CIREL study will gather data on patients with colorectal adenocarcinoma and liver-only or liver-dominant metastatic disease treated with transarterial chemoembolization (TACE) using LifePearl microspheres (Terumo Europe) loaded with Irinotecan in specialist hospitals across Europe.

According to CIRSE, the study aims to observe and categorize the real-life use of the LifePearl device in the context of patient’s cancer treatment and will also collect extensive quality-of-life data to learn more about the palliative aspect of TACE. Previous research on LifePearl microspheres included only preclinical and pharmacokinetic studies.

CIREL is designed and run exclusively by CIRSE and is funded by a grant provided by Terumo Medical Europe. Prof. Philippe L. Pereira, MD, is Co-Chairperson of the CIREL Steering Committee.

In the CIRSE announcement, Prof. Pereira commented, “CIREL will greatly contribute to the collection of scientific knowledge and clinical data in one of interventional radiology’s most dynamic and promising fields and help us better understand what could be the potential indications to treat patients with TACE.” Prof. Pereira is Head of Radiology, Minimally Invasive Therapies, and Nuclear Medicine at Klinikum am Gesundbrunnen in Heilbronn, Germany.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.